サンプル依頼リスト カート
  • English
  • Traditional Chinese
  • Simplified Chinese
デフォルト表紙
市場調査レポート
商品コード
1706760

キナーゼ阻害剤市場：世界の産業分析、規模、シェア、成長、動向、2024-2034年予測

Kinase Inhibitors Market - Global Industry Analysis, Size, Share, Growth, Trends, and Forecast, 2024-2034

出版日
ページ情報
英文 219 Pages
納期
2～10営業日
カスタマイズ可能
価格
価格表記: USDを日本円(税抜)に換算
本日の銀行送金レート: 1USD=144.06円
キナーゼ阻害剤市場：世界の産業分析、規模、シェア、成長、動向、2024-2034年予測
出版日: 2025年02月10日
発行: Transparency Market Research
ページ情報: 英文 219 Pages
納期: 2～10営業日
GIIご利用のメリット
  • 全表示
  • 概要
  • 図表
  • 目次
概要

キナーゼ阻害剤市場- 調査範囲

TMRの調査レポート「世界のキナーゼ阻害剤市場」は、2024年から2034年までの予測期間における市場の指標に関する貴重な洞察を得るために、過去だけでなく現在の成長動向と機会についても調査しています。本レポートでは、2024年を基準年、2034年を予測年として、2018年から2034年までの世界のキナーゼ阻害剤市場の収益と予測を提供します。また、2024年から2034年までの世界のキナーゼ阻害剤市場の複合年間成長率（CAGR %）も掲載しています。

本レポートは広範な調査を経て作成されています。1次調査では、アナリストが主要オピニオンリーダー、業界リーダー、オピニオンメーカーへのインタビューを実施しました。2次調査では、主要企業の製品資料、アニュアルレポート、プレスリリース、関連資料などを参照し、キナーゼ阻害剤市場を推察しました。

市場スナップショット
2023年の市場規模 580億9,010万米ドル
2034年の市場規模 899億2,980万米ドル
CAGR 3.9%

当レポートでは、世界のキナーゼ阻害剤市場の競合情勢について調査しています。世界のキナーゼ阻害剤市場で事業を展開する主要企業が特定され、各企業が様々な属性でプロファイルされています。企業概要、財務状況、最近の動向、SWOTが本レポートで紹介されている世界のキナーゼ阻害剤市場におけるプレイヤーの属性です。

目次

第1章 序文

第2章 前提条件と調査手法

第3章 エグゼクティブサマリー： 世界市場

第4章 市場概要

  • イントロダクション
  • 概要
  • 市場力学
  • 世界の市場分析と予測, 2020-2034年

第5章 主要洞察

  • 主要な業界イベント
  • PESTEL分析
  • 主要国・地域別の規制シナリオ
  • ポーターのファイブフォース分析
  • 製品/ブランド分析
  • サプライチェーン分析
  • パイプライン分析

第6章 世界の市場分析と予測：タイプ別

  • イントロダクションと定義
  • 主な調査結果/進展
  • 市場金額予測：タイプ別, 2020-2034年
    • 非受容体チロシン
      • ブルトン型チロシンキナーゼ（BTK）阻害剤
      • BCR-ABL
      • ヤヌスキナーゼ（JAK）阻害剤
      • 間葉系上皮細胞転換増殖因子（c-MET）
      • 脾臓チロシンキナーゼ（SYK）阻害剤
      • その他
    • 受容体チロシン
      • VEGFR
      • PDGFR
      • EGFR
      • アルク
      • その他
    • マルチ
    • セリン/スレオニン
    • プロテインキナーゼC阻害剤
    • RHO
    • その他
  • タイプ別市場の魅力

第7章 世界の市場分析と予測：投与経路別

  • イントロダクションと定義
  • 主な調査結果/進展
  • 市場金額予測：投与経路別, 2020-2034年
    • 経口
    • 非経口剤およびその他
  • 投与経路別の市場の魅力

第8章 世界の市場分析と予測：用途別

  • イントロダクションと定義
  • 主な調査結果/進展
  • 市場金額予測：用途別, 2020-2034年
    • 腫瘍学
      • 乳がん
      • 白血病
      • 腎臓がん
      • 肺がん
      • 黒色腫
      • 大腸がん
      • その他
    • 炎症性疾患
    • その他
  • 用途別の市場の魅力

第9章 世界の市場分析と予測：最終用途別

  • イントロダクションと定義
  • 主な調査結果/進展
  • 市場金額予測：最終用途別, 2020-2034年
    • 病院薬局
    • 独立系薬局
    • オンライン薬局
  • 最終用途別の市場の魅力

第10章 世界の市場分析と予測：地域別

  • 主な調査結果
  • 市場金額予測：地域別
    • 北米
    • 欧州
    • アジア太平洋地域
    • ラテンアメリカ
    • 中東・アフリカ
  • 地域別市場の魅力

第11章 北米の市場分析と予測

  • 米国
  • カナダ

第12章 欧州の市場分析と予測

  • ドイツ
  • 英国
  • フランス
  • イタリア
  • スペイン
  • その他欧州地域

第13章 アジア太平洋地域の市場分析と予測

  • 中国
  • インド
  • 日本
  • オーストラリアとニュージーランド
  • その他アジア太平洋地域

第14章 ラテンアメリカの市場分析と予測

  • ブラジル
  • メキシコ
  • その他ラテンアメリカ地域

第15章 中東・アフリカの市場分析と予測

  • GCC諸国
  • 南アフリカ
  • その他中東・アフリカ

第16章 競合情勢

  • 市場企業-競合マトリックス（企業階層別・規模別）
  • 市場シェア分析企業別（2023年）
  • 企業プロファイル
    • Boehringer Ingelheim International GmbH
    • Novartis AG
    • AstraZeneca plc
    • Pfizer, Inc.
    • F. Hoffmann-La Roche Ltd
    • Bristol-Myers Squibb Company
    • Bayer AG
    • Johnson & Johnson Service, Inc.
    • Merck & Co., Inc.
    • Takeda Pharmaceuticals
    • Eisai Co., Ltd.
    • GSK Plc.
    • Eli Lilly
    • Alcon
図表

List of Tables

  • Table 01: Global Kinase Inhibitors Market Value (US$ Mn) Forecast, By Type, 2020-2034
  • Table 02: Global Kinase Inhibitors Market Value (US$ Mn) Forecast, By Non-receptor Tyrosine Kinase Inhibitors, 2020-2034
  • Table 03: Global Kinase Inhibitors Market Value (US$ Mn) Forecast, By Receptor Tyrosine Kinase Inhibitors, 2020-2034
  • Table 04: Global Kinase Inhibitors Market Value (US$ Mn) Forecast, By Route of Administration, 2020-2034
  • Table 05: Global Kinase Inhibitors Market Value (US$ Mn) Forecast, By Application, 2020-2034
  • Table 06: Global Kinase Inhibitors Market Value (US$ Mn) Forecast, By Oncology, 2020-2034
  • Table 07: Global Kinase Inhibitors Market Value (US$ Mn) Forecast, By End-user, 2020-2034
  • Table 08: Global Kinase Inhibitors Market Value (US$ Mn) Forecast, By Region, 2020-2034
  • Table 09: North America - Kinase Inhibitors Market Value (US$ Mn) Forecast, by Country, 2020-2034
  • Table 10: North America Kinase Inhibitors Market Value (US$ Mn) Forecast, By Type, 2020-2034
  • Table 11: North America Kinase Inhibitors Market Value (US$ Mn) Forecast, By Non-receptor Tyrosine Kinase Inhibitors, 2020-2034
  • Table 12: North America Kinase Inhibitors Market Value (US$ Mn) Forecast, By Receptor Tyrosine Kinase Inhibitors, 2020-2034
  • Table 13: North America Kinase Inhibitors Market Value (US$ Mn) Forecast, By Route of Administration, 2020-2034
  • Table 14: North America Kinase Inhibitors Market Value (US$ Mn) Forecast, By Application, 2020-2034
  • Table 15: North America Kinase Inhibitors Market Value (US$ Mn) Forecast, By Oncology, 2020-2034
  • Table 16: North America Kinase Inhibitors Market Value (US$ Mn) Forecast, By End-user, 2020-2034
  • Table 17: Europe - Kinase Inhibitors Market Value (US$ Mn) Forecast, by Country, 2020-2034
  • Table 18: Europe Kinase Inhibitors Market Value (US$ Mn) Forecast, By Type, 2020-2034
  • Table 19: Europe Kinase Inhibitors Market Value (US$ Mn) Forecast, By Non-receptor Tyrosine Kinase Inhibitors, 2020-2034
  • Table 20: Europe Kinase Inhibitors Market Value (US$ Mn) Forecast, By Receptor Tyrosine Kinase Inhibitors, 2020-2034
  • Table 21: Europe Kinase Inhibitors Market Value (US$ Mn) Forecast, By Route of Administration, 2020-2034
  • Table 22: Europe Kinase Inhibitors Market Value (US$ Mn) Forecast, By Application, 2020-2034
  • Table 23: Europe Kinase Inhibitors Market Value (US$ Mn) Forecast, By Oncology, 2020-2034
  • Table 24: Europe Kinase Inhibitors Market Value (US$ Mn) Forecast, By End-user, 2020-2034
  • Table 25: Asia Pacific - Kinase Inhibitors Market Value (US$ Mn) Forecast, by Country, 2020-2034
  • Table 26: Asia Pacific Kinase Inhibitors Market Value (US$ Mn) Forecast, By Type, 2020-2034
  • Table 27: Asia Pacific Kinase Inhibitors Market Value (US$ Mn) Forecast, By Non-receptor Tyrosine Kinase Inhibitors, 2020-2034
  • Table 28: Asia Pacific Kinase Inhibitors Market Value (US$ Mn) Forecast, By Receptor Tyrosine Kinase Inhibitors, 2020-2034
  • Table 29: Asia Pacific Kinase Inhibitors Market Value (US$ Mn) Forecast, By Route of Administration, 2020-2034
  • Table 30: Asia Pacific Kinase Inhibitors Market Value (US$ Mn) Forecast, By Application, 2020-2034
  • Table 31: Asia Pacific Kinase Inhibitors Market Value (US$ Mn) Forecast, By Oncology, 2020-2034
  • Table 32: Asia Pacific Kinase Inhibitors Market Value (US$ Mn) Forecast, By End-user, 2020-2034
  • Table 33: Latin America - Kinase Inhibitors Market Value (US$ Mn) Forecast, by Country, 2020-2034
  • Table 34: Latin America Kinase Inhibitors Market Value (US$ Mn) Forecast, By Type, 2020-2034
  • Table 35: Latin America Kinase Inhibitors Market Value (US$ Mn) Forecast, By Non-receptor Tyrosine Kinase Inhibitors, 2020-2034
  • Table 36: Latin America Kinase Inhibitors Market Value (US$ Mn) Forecast, By Receptor Tyrosine Kinase Inhibitors, 2020-2034
  • Table 37: Latin America Kinase Inhibitors Market Value (US$ Mn) Forecast, By Route of Administration, 2020-2034
  • Table 38: Latin America Kinase Inhibitors Market Value (US$ Mn) Forecast, By Application, 2020-2034
  • Table 39: Latin America Kinase Inhibitors Market Value (US$ Mn) Forecast, By Oncology, 2020-2034
  • Table 40: Latin America Kinase Inhibitors Market Value (US$ Mn) Forecast, By End-user, 2020-2034
  • Table 41: Middle East & Africa - Kinase Inhibitors Market Value (US$ Mn) Forecast, by Country, 2020-2034
  • Table 42: Middle East & Africa Kinase Inhibitors Market Value (US$ Mn) Forecast, By Type, 2020-2034
  • Table 43: Middle East & Africa Kinase Inhibitors Market Value (US$ Mn) Forecast, By Non-receptor Tyrosine Kinase Inhibitors, 2020-2034
  • Table 44: Middle East & Africa Kinase Inhibitors Market Value (US$ Mn) Forecast, By Receptor Tyrosine Kinase Inhibitors, 2020-2034
  • Table 45: Middle East & Africa Kinase Inhibitors Market Value (US$ Mn) Forecast, By Route of Administration, 2020-2034
  • Table 46: Middle East & Africa Kinase Inhibitors Market Value (US$ Mn) Forecast, By Application, 2020-2034
  • Table 47: Middle East & Africa Kinase Inhibitors Market Value (US$ Mn) Forecast, By Oncology, 2020-2034
  • Table 48: Middle East & Africa Kinase Inhibitors Market Value (US$ Mn) Forecast, By End-user, 2020-2034

List of Figures

  • Figure 01: Global Kinase Inhibitors Market Value Share Analysis, By Type, 2023 and 2034
  • Figure 02: Global Kinase Inhibitors Market Attractiveness Analysis, By Type, 2024-2034
  • Figure 03: Global Kinase Inhibitors Market Revenue (US$ Mn), by Non-receptor Tyrosine Kinase Inhibitors, 2020-2034
  • Figure 04: Global Kinase Inhibitors Market Revenue (US$ Mn), by Receptor Tyrosine Kinase Inhibitors, 2020-2034
  • Figure 05: Global Kinase Inhibitors Market Revenue (US$ Mn), by Multikinase Inhibitors, 2020-2034
  • Figure 06: Global Kinase Inhibitors Market Revenue (US$ Mn), by Serine/Threonine Kinase Inhibitors, 2020-2034
  • Figure 07: Global Kinase Inhibitors Market Revenue (US$ Mn), by Protein Kinase C Inhibitors, 2020-2034
  • Figure 08: Global Kinase Inhibitors Market Revenue (US$ Mn), by RHO Kinase Inhibitors, 2020-2034
  • Figure 09: Global Kinase Inhibitors Market Revenue (US$ Mn), by Others, 2020-2034
  • Figure 10: Global Kinase Inhibitors Market Value Share Analysis, By Route of Administration, 2023 and 2034
  • Figure 11: Global Kinase Inhibitors Market Attractiveness Analysis, By Route of Administration, 2024-2034
  • Figure 12: Global Kinase Inhibitors Market Revenue (US$ Mn), by Oral, 2020-2034
  • Figure 13: Global Kinase Inhibitors Market Revenue (US$ Mn), by Parenteral, 2020-2034
  • Figure 14: Global Kinase Inhibitors Market Value Share Analysis, By Application, 2023 and 2034
  • Figure 15: Global Kinase Inhibitors Market Attractiveness Analysis, By Application, 2024-2034
  • Figure 16: Global Kinase Inhibitors Market Revenue (US$ Mn), by Breast Cancer, 2020-2034
  • Figure 17: Global Kinase Inhibitors Market Revenue (US$ Mn), by Chronic myeloid leukemia (CML), 2020-2034
  • Figure 18: Global Kinase Inhibitors Market Revenue (US$ Mn), by Renal Cancers, 2020-2034
  • Figure 19: Global Kinase Inhibitors Market Revenue (US$ Mn), by Lung Cancer, 2020-2034
  • Figure 20: Global Kinase Inhibitors Market Revenue (US$ Mn), by Metastatic melanoma, 2020-2034
  • Figure 21: Global Kinase Inhibitors Market Revenue (US$ Mn), by Soft tissue sarcoma, 2020-2034
  • Figure 22: Global Kinase Inhibitors Market Revenue (US$ Mn), by Others, 2020-2034
  • Figure 23: Global Kinase Inhibitors Market Value Share Analysis, By End-user, 2023 and 2034
  • Figure 24: Global Kinase Inhibitors Market Attractiveness Analysis, By End-user, 2024-2034
  • Figure 25: Global Kinase Inhibitors Market Revenue (US$ Mn), by Hospital Pharmacies, 2020-2034
  • Figure 26: Global Kinase Inhibitors Market Revenue (US$ Mn), by Independent Pharmacies, 2020-2034
  • Figure 27: Global Kinase Inhibitors Market Revenue (US$ Mn), by Online Pharmacies, 2020-2034
  • Figure 28: Global Kinase Inhibitors Market Value Share Analysis, By Region, 2023 and 2034
  • Figure 29: Global Kinase Inhibitors Market Attractiveness Analysis, By Region, 2024-2034
  • Figure 30: North America Kinase Inhibitors Market Value (US$ Mn) Forecast, 2020-2034
  • Figure 31: North America Kinase Inhibitors Market Value Share Analysis, by Country, 2023 and 2034
  • Figure 32: North America Kinase Inhibitors Market Attractiveness Analysis, by Country, 2024-2034
  • Figure 33: North America Kinase Inhibitors Market Value Share Analysis, By Type, 2023 and 2034
  • Figure 34: North America Kinase Inhibitors Market Attractiveness Analysis, By Type, 2024-2034
  • Figure 35: North America Kinase Inhibitors Market Value Share Analysis, By Route of Administration, 2023 and 2034
  • Figure 36: North America Kinase Inhibitors Market Attractiveness Analysis, By Route of Administration, 2024-2034
  • Figure 37: North America Kinase Inhibitors Market Value Share Analysis, By Application, 2023 and 2034
  • Figure 38: North America Kinase Inhibitors Market Attractiveness Analysis, By Application, 2024-2034
  • Figure 39: North America Kinase Inhibitors Market Value Share Analysis, By End-user, 2023 and 2034
  • Figure 40: North America Kinase Inhibitors Market Attractiveness Analysis, By End-user, 2024-2034
  • Figure 41: Europe Kinase Inhibitors Market Value (US$ Mn) Forecast, 2020-2034
  • Figure 42: Europe Kinase Inhibitors Market Value Share Analysis, by Country, 2023 and 2034
  • Figure 43: Europe Kinase Inhibitors Market Attractiveness Analysis, by Country, 2024-2034
  • Figure 44: Europe Kinase Inhibitors Market Value Share Analysis, By Type, 2023 and 2034
  • Figure 45: Europe Kinase Inhibitors Market Attractiveness Analysis, By Type, 2024-2034
  • Figure 46: Europe Kinase Inhibitors Market Value Share Analysis, By Route of Administration, 2023 and 2034
  • Figure 47: Europe Kinase Inhibitors Market Attractiveness Analysis, By Route of Administration, 2024-2034
  • Figure 48: Europe Kinase Inhibitors Market Value Share Analysis, By Application, 2023 and 2034
  • Figure 49: Europe Kinase Inhibitors Market Attractiveness Analysis, By Application, 2024-2034
  • Figure 50: Europe Kinase Inhibitors Market Value Share Analysis, By End-user, 2023 and 2034
  • Figure 51: Europe Kinase Inhibitors Market Attractiveness Analysis, By End-user, 2024-2034
  • Figure 52: Asia Pacific Kinase Inhibitors Market Value (US$ Mn) Forecast, 2020-2034
  • Figure 53: Asia Pacific Kinase Inhibitors Market Value Share Analysis, by Country, 2023 and 2034
  • Figure 54: Asia Pacific Kinase Inhibitors Market Attractiveness Analysis, by Country, 2024-2034
  • Figure 55: Asia Pacific Kinase Inhibitors Market Value Share Analysis, By Type, 2023 and 2034
  • Figure 56: Asia Pacific Kinase Inhibitors Market Attractiveness Analysis, By Type, 2024-2034
  • Figure 57: Asia Pacific Kinase Inhibitors Market Value Share Analysis, By Route of Administration, 2023 and 2034
  • Figure 58: Asia Pacific Kinase Inhibitors Market Attractiveness Analysis, By Route of Administration, 2024-2034
  • Figure 59: Asia Pacific Kinase Inhibitors Market Value Share Analysis, By Application, 2023 and 2034
  • Figure 60: Asia Pacific Kinase Inhibitors Market Attractiveness Analysis, By Application, 2024-2034
  • Figure 61: Asia Pacific Kinase Inhibitors Market Value Share Analysis, By End-user, 2023 and 2034
  • Figure 62: Asia Pacific Kinase Inhibitors Market Attractiveness Analysis, By End-user, 2024-2034
  • Figure 63: Latin America Kinase Inhibitors Market Value (US$ Mn) Forecast, 2020-2034
  • Figure 64: Latin America Kinase Inhibitors Market Value Share Analysis, by Country, 2023 and 2034
  • Figure 65: Latin America Kinase Inhibitors Market Attractiveness Analysis, by Country, 2024-2034
  • Figure 66: Latin America Kinase Inhibitors Market Value Share Analysis, By Type, 2023 and 2034
  • Figure 67: Latin America Kinase Inhibitors Market Attractiveness Analysis, By Type, 2024-2034
  • Figure 68: Latin America Kinase Inhibitors Market Value Share Analysis, By Route of Administration, 2023 and 2034
  • Figure 69: Latin America Kinase Inhibitors Market Attractiveness Analysis, By Route of Administration, 2024-2034
  • Figure 70: Latin America Kinase Inhibitors Market Value Share Analysis, By Application, 2023 and 2034
  • Figure 71: Latin America Kinase Inhibitors Market Attractiveness Analysis, By Application, 2024-2034
  • Figure 72: Latin America Kinase Inhibitors Market Value Share Analysis, By End-user, 2023 and 2034
  • Figure 73: Latin America Kinase Inhibitors Market Attractiveness Analysis, By End-user, 2024-2034
  • Figure 74: Middle East & Africa Kinase Inhibitors Market Value (US$ Mn) Forecast, 2020-2034
  • Figure 75: Middle East & Africa Kinase Inhibitors Market Value Share Analysis, by Country, 2023 and 2034
  • Figure 76: Middle East & Africa Kinase Inhibitors Market Attractiveness Analysis, by Country, 2024-2034
  • Figure 77: Middle East & Africa Kinase Inhibitors Market Value Share Analysis, By Type, 2023 and 2034
  • Figure 78: Middle East & Africa Kinase Inhibitors Market Attractiveness Analysis, By Type, 2024-2034
  • Figure 79: Middle East & Africa Kinase Inhibitors Market Value Share Analysis, By Route of Administration, 2023 and 2034
  • Figure 80: Middle East & Africa Kinase Inhibitors Market Attractiveness Analysis, By Route of Administration, 2024-2034
  • Figure 81: Middle East & Africa Kinase Inhibitors Market Value Share Analysis, By Application, 2023 and 2034
  • Figure 82: Middle East & Africa Kinase Inhibitors Market Attractiveness Analysis, By Application, 2024-2034
  • Figure 83: Middle East & Africa Kinase Inhibitors Market Value Share Analysis, By End-user, 2023 and 2034
  • Figure 84: Middle East & Africa Kinase Inhibitors Market Attractiveness Analysis, By End-user, 2024-2034
目次
Product Code: TMRGL818

Kinase Inhibitors Market - Scope of Report

TMR's report on the global kinase inhibitors market studies the past as well as the current growth trends and opportunities to gain valuable insights of the indicators of the market during the forecast period from 2024 to 2034. The report provides revenue of the global kinase inhibitors market for the period 2018-2034, considering 2024 as the base year and 2034 as the forecast year. The report also provides the compound annual growth rate (CAGR %) of the global kinase inhibitors market from 2024 to 2034.

The report has been prepared after an extensive research. Primary research involved bulk of the research efforts, wherein analysts carried out interviews with key opinion leaders, industry leaders, and opinion makers. Secondary research involved referring to key players' product literature, annual reports, press releases, and relevant documents to understand the kinase inhibitors market.

Market Snapshot
Market Value in 2023US$ 58090.1 Mn
Market Value in 2034US$ 89929.8 Mn
CAGR3.9%

Secondary research also included Internet sources, statistical data from government agencies, websites, and trade associations. Analysts employed a combination of top-down and bottom-up approaches to study various attributes of the global kinase inhibitors market.

The report includes an elaborate executive summary, along with a snapshot of the growth behavior of various segments included in the scope of the study. Moreover, the report throws light on the changing competitive dynamics in the global kinase inhibitors market. These serve as valuable tools for existing market players as well as for entities interested in participating in the global kinase inhibitors market.

The report delves into the competitive landscape of the global kinase inhibitors market. Key players operating in the global kinase inhibitors market have been identified and each one of these has been profiled in terms of various attributes. Company overview, financial standings, recent developments, and SWOT are the attributes of players in the global kinase inhibitors market profiled in this report.

Key Questions Answered in Global kinase inhibitors Market Report:

  • What is the sales/revenue generated by kinase inhibitors across all regions during the forecast period?
  • What are the opportunities in the global kinase inhibitors market?
  • What are the major drivers, restraints, opportunities, and threats in the market?
  • Which regional market is set to expand at the fastest CAGR during the forecast period?
  • Which segment is expected to generate the highest revenue globally in 2034?
  • Which segment is projected to expand at the highest CAGR during the forecast period?
  • What are the market positions of different companies operating in the global market?

Kinase Inhibitors Market - Research Objectives and Research Approach

The comprehensive report on the global kinase inhibitors market begins with an overview, followed by the scope and objectives of the study. The report provides detailed explanation of the objectives behind this study and key vendors and distributors operating in the market and regulatory scenario for approval of products.

For reading comprehensibility, the report has been compiled in a chapter-wise layout, with each section divided into smaller ones. The report comprises an exhaustive collection of graphs and tables that are appropriately interspersed. Pictorial representation of actual and projected values of key segments is visually appealing to readers. This also allows comparison of the market shares of key segments in the past and at the end of the forecast period.

The report analyzes the global kinase inhibitors market in terms of product, end-user, and region. Key segments under each criterion have been studied at length, and the market share for each of these at the end of 2034 has been provided. Such valuable insights enable market stakeholders in making informed business decisions for investment in the global kinase inhibitors market.

Table of Contents

1. Preface

  • 1.1. Market Definition and Scope
  • 1.2. Market Segmentation
  • 1.3. Key Research Objectives
  • 1.4. Research Highlights

2. Assumptions and Research Methodology

3. Executive Summary : Global Kinase Inhibitors Market

4. Market Overview

  • 4.1. Introduction
    • 4.1.1. Segment Definition
  • 4.2. Overview
  • 4.3. Market Dynamics
    • 4.3.1. Drivers
    • 4.3.2. Restraints
    • 4.3.3. Opportunities
  • 4.4. Global Kinase Inhibitors Market Analysis and Forecasts, 2020-2034
    • 4.4.1. Market Revenue Projections (US$ Mn)

5. Key Insights

  • 5.1. Key Industry Events
  • 5.2. PESTEL Analysis
  • 5.3. Regulatory Scenario by Key Countries/Regions
  • 5.4. PORTER's Five Forces Analysis
  • 5.5. Product/Brand Analysis
  • 5.6. Supply Chain Analysis
  • 5.7. Pipeline Analysis

6. Global Kinase Inhibitors Market Analysis and Forecasts, By Type

  • 6.1. Introduction & Definition
  • 6.2. Key Findings / Developments
  • 6.3. Market Value Forecast By Type, 2020-2034
    • 6.3.1. Non-receptor Tyrosine Kinase Inhibitors
      • 6.3.1.1. Bruton's Tyrosine Kinase (BTK) Inhibitors
      • 6.3.1.2. BCR-ABL
      • 6.3.1.3. Janus Kinase (JAK) Inhibitor
      • 6.3.1.4. Mesenchymal Epithelial Transition Growth Factor (c-MET)
      • 6.3.1.5. Spleen Tyrosine Kinase (SYK) Inhibitors
      • 6.3.1.6. Others
    • 6.3.2. Receptor Tyrosine Kinase Inhibitors
      • 6.3.2.1. VEGFR
      • 6.3.2.2. PDGFR
      • 6.3.2.3. EGFR
      • 6.3.2.4. ALK
      • 6.3.2.5. Others
    • 6.3.3. Multikinase Inhibitors
    • 6.3.4. Serine/Threonine Kinase Inhibitors
    • 6.3.5. Protein Kinase C Inhibitors
    • 6.3.6. RHO Kinase Inhibitors
    • 6.3.7. Others
  • 6.4. Market Attractiveness By Type

7. Global Kinase Inhibitors Market Analysis and Forecasts, By Route of Administration

  • 7.1. Introduction & Definition
  • 7.2. Key Findings / Developments
  • 7.3. Market Value Forecast By Route of Administration, 2020-2034
    • 7.3.1. Oral
    • 7.3.2. Parenteral & Others
  • 7.4. Market Attractiveness By Route of Administration

8. Global Kinase Inhibitors Market Analysis and Forecasts, By Application

  • 8.1. Introduction & Definition
  • 8.2. Key Findings / Developments
  • 8.3. Market Value Forecast By Application, 2020-2034
    • 8.3.1. Oncology
      • 8.3.1.1. Breast Cancer
      • 8.3.1.2. Leukemia
      • 8.3.1.3. Renal Cancers
      • 8.3.1.4. Lung Cancer
      • 8.3.1.5. Melanoma
      • 8.3.1.6. Colorectal Cancer
      • 8.3.1.7. Others
    • 8.3.2. Inflammatory Disorders
    • 8.3.3. Others
  • 8.4. Market Attractiveness By Application

9. Global Kinase Inhibitors Market Analysis and Forecasts, By End-user

  • 9.1. Introduction & Definition
  • 9.2. Key Findings / Developments
  • 9.3. Market Value Forecast By End-user, 2020-2034
    • 9.3.1. Hospital Pharmacies
    • 9.3.2. Independent Pharmacies
    • 9.3.3. Online Pharmacies
  • 9.4. Market Attractiveness By End-user

10. Global Kinase Inhibitors Market Analysis and Forecasts, By Region

  • 10.1. Key Findings
  • 10.2. Market Value Forecast By Region
    • 10.2.1. North America
    • 10.2.2. Europe
    • 10.2.3. Asia Pacific
    • 10.2.4. Latin America
    • 10.2.5. Middle East & Africa
  • 10.3. Market Attractiveness By Region

11. North America Kinase Inhibitors Market Analysis and Forecast

  • 11.1. Introduction
    • 11.1.1. Key Findings
  • 11.2. Market Value Forecast By Type, 2020-2034
    • 11.2.1. Non-receptor Tyrosine Kinase Inhibitors
      • 11.2.1.1. Bruton's Tyrosine Kinase (BTK) Inhibitors
      • 11.2.1.2. BCR-ABL
      • 11.2.1.3. Janus Kinase (JAK) Inhibitor
      • 11.2.1.4. Mesenchymal Epithelial Transition Growth Factor (c-MET)
      • 11.2.1.5. Spleen Tyrosine Kinase (SYK) Inhibitors
      • 11.2.1.6. Others
    • 11.2.2. Receptor Tyrosine Kinase Inhibitors
      • 11.2.2.1. VEGFR
      • 11.2.2.2. PDGFR
      • 11.2.2.3. EGFR
      • 11.2.2.4. ALK
      • 11.2.2.5. Others
    • 11.2.3. Multikinase Inhibitors
    • 11.2.4. Serine/Threonine Kinase Inhibitors
    • 11.2.5. Protein Kinase C Inhibitors
    • 11.2.6. RHO Kinase Inhibitors
    • 11.2.7. Others
  • 11.3. Market Value Forecast By Route of Administration, 2020-2034
    • 11.3.1. Oral
    • 11.3.2. Parenteral & Others
  • 11.4. Market Value Forecast By Application, 2020-2034
    • 11.4.1. Oncology
      • 11.4.1.1. Breast Cancer
      • 11.4.1.2. Leukemia
      • 11.4.1.3. Renal Cancers
      • 11.4.1.4. Lung Cancer
      • 11.4.1.5. Melanoma
      • 11.4.1.6. Colorectal Cancer
      • 11.4.1.7. Others
    • 11.4.2. Inflammatory Disorders
    • 11.4.3. Others
  • 11.5. Market Value Forecast By End-user, 2020-2034
    • 11.5.1. Hospital Pharmacies
    • 11.5.2. Independent Pharmacies
    • 11.5.3. Online Pharmacies
  • 11.6. Market Value Forecast By Country, 2020-2034
    • 11.6.1. U.S.
    • 11.6.2. Canada
  • 11.7. Market Attractiveness Analysis
    • 11.7.1. By Type
    • 11.7.2. By Route of Administration
    • 11.7.3. By Application
    • 11.7.4. By End-user
    • 11.7.5. By Country

12. Europe Kinase Inhibitors Market Analysis and Forecast

  • 12.1. Introduction
    • 12.1.1. Key Findings
  • 12.2. Market Value Forecast By Type, 2020-2034
    • 12.2.1. Non-receptor Tyrosine Kinase Inhibitors
      • 12.2.1.1. Bruton's Tyrosine Kinase (BTK) Inhibitors
      • 12.2.1.2. BCR-ABL
      • 12.2.1.3. Janus Kinase (JAK) Inhibitor
      • 12.2.1.4. Mesenchymal Epithelial Transition Growth Factor (c-MET)
      • 12.2.1.5. Spleen Tyrosine Kinase (SYK) Inhibitors
      • 12.2.1.6. Others
    • 12.2.2. Receptor Tyrosine Kinase Inhibitors
      • 12.2.2.1. VEGFR
      • 12.2.2.2. PDGFR
      • 12.2.2.3. EGFR
      • 12.2.2.4. ALK
      • 12.2.2.5. Others
    • 12.2.3. Multikinase Inhibitors
    • 12.2.4. Serine/Threonine Kinase Inhibitors
    • 12.2.5. Protein Kinase C Inhibitors
    • 12.2.6. RHO Kinase Inhibitors
    • 12.2.7. Others
  • 12.3. Market Value Forecast By Route of Administration, 2020-2034
    • 12.3.1. Oral
    • 12.3.2. Parenteral & Others
  • 12.4. Market Value Forecast By Application, 2020-2034
    • 12.4.1. Oncology
      • 12.4.1.1. Breast Cancer
      • 12.4.1.2. Leukemia
      • 12.4.1.3. Renal Cancers
      • 12.4.1.4. Lung Cancer
      • 12.4.1.5. Melanoma
      • 12.4.1.6. Colorectal Cancer
      • 12.4.1.7. Others
    • 12.4.2. Inflammatory Disorders
    • 12.4.3. Others
  • 12.5. Market Value Forecast By End-user, 2020-2034
    • 12.5.1. Hospital Pharmacies
    • 12.5.2. Independent Pharmacies
    • 12.5.3. Online Pharmacies
  • 12.6. Market Value Forecast By Country/Sub-region, 2020-2034
    • 12.6.1. Germany
    • 12.6.2. U.K.
    • 12.6.3. France
    • 12.6.4. Italy
    • 12.6.5. Spain
    • 12.6.6. Rest of Europe
  • 12.7. Market Attractiveness Analysis
    • 12.7.1. By Type
    • 12.7.2. By Route of Administration
    • 12.7.3. By Application
    • 12.7.4. By End-user
    • 12.7.5. By Country/Sub-region

13. Asia Pacific Kinase Inhibitors Market Analysis and Forecast

  • 13.1. Introduction
    • 13.1.1. Key Findings
  • 13.2. Market Value Forecast By Type, 2020-2034
    • 13.2.1. Non-receptor Tyrosine Kinase Inhibitors
      • 13.2.1.1. Bruton's Tyrosine Kinase (BTK) Inhibitors
      • 13.2.1.2. BCR-ABL
      • 13.2.1.3. Janus Kinase (JAK) Inhibitor
      • 13.2.1.4. Mesenchymal Epithelial Transition Growth Factor (c-MET)
      • 13.2.1.5. Spleen Tyrosine Kinase (SYK) Inhibitors
      • 13.2.1.6. Others
    • 13.2.2. Receptor Tyrosine Kinase Inhibitors
      • 13.2.2.1. VEGFR
      • 13.2.2.2. PDGFR
      • 13.2.2.3. EGFR
      • 13.2.2.4. ALK
      • 13.2.2.5. Others
    • 13.2.3. Multikinase Inhibitors
    • 13.2.4. Serine/Threonine Kinase Inhibitors
    • 13.2.5. Protein Kinase C Inhibitors
    • 13.2.6. RHO Kinase Inhibitors
    • 13.2.7. Others
  • 13.3. Market Value Forecast By Route of Administration, 2020-2034
    • 13.3.1. Oral
    • 13.3.2. Parenteral & Others
  • 13.4. Market Value Forecast By Application, 2020-2034
    • 13.4.1. Oncology
      • 13.4.1.1. Breast Cancer
      • 13.4.1.2. Leukemia
      • 13.4.1.3. Renal Cancers
      • 13.4.1.4. Lung Cancer
      • 13.4.1.5. Melanoma
      • 13.4.1.6. Colorectal Cancer
      • 13.4.1.7. Others
    • 13.4.2. Inflammatory Disorders
    • 13.4.3. Others
  • 13.5. Market Value Forecast By End-user, 2020-2034
    • 13.5.1. Hospital Pharmacies
    • 13.5.2. Independent Pharmacies
    • 13.5.3. Online Pharmacies
  • 13.6. Market Value Forecast By Country/Sub-region, 2020-2034
    • 13.6.1. China
    • 13.6.2. India
    • 13.6.3. Japan
    • 13.6.4. Australia & New Zealand
    • 13.6.5. Rest of Asia Pacific
  • 13.7. Market Attractiveness Analysis
    • 13.7.1. By Type
    • 13.7.2. By Route of Administration
    • 13.7.3. By Application
    • 13.7.4. By End-user
    • 13.7.5. By Country/Sub-region

14. Latin America Kinase Inhibitors Market Analysis and Forecast

  • 14.1. Introduction
    • 14.1.1. Key Findings
  • 14.2. Market Value Forecast By Type, 2020-2034
    • 14.2.1. Non-receptor Tyrosine Kinase Inhibitors
      • 14.2.1.1. Bruton's Tyrosine Kinase (BTK) Inhibitors
      • 14.2.1.2. BCR-ABL
      • 14.2.1.3. Janus Kinase (JAK) Inhibitor
      • 14.2.1.4. Mesenchymal Epithelial Transition Growth Factor (c-MET)
      • 14.2.1.5. Spleen Tyrosine Kinase (SYK) Inhibitors
      • 14.2.1.6. Others
    • 14.2.2. Receptor Tyrosine Kinase Inhibitors
      • 14.2.2.1. VEGFR
      • 14.2.2.2. PDGFR
      • 14.2.2.3. EGFR
      • 14.2.2.4. ALK
      • 14.2.2.5. Others
    • 14.2.3. Multikinase Inhibitors
    • 14.2.4. Serine/Threonine Kinase Inhibitors
    • 14.2.5. Protein Kinase C Inhibitors
    • 14.2.6. RHO Kinase Inhibitors
    • 14.2.7. Others
  • 14.3. Market Value Forecast By Route of Administration, 2020-2034
    • 14.3.1. Oral
    • 14.3.2. Parenteral & Others
  • 14.4. Market Value Forecast By Application, 2020-2034
    • 14.4.1. Oncology
      • 14.4.1.1. Breast Cancer
      • 14.4.1.2. Leukemia
      • 14.4.1.3. Renal Cancers
      • 14.4.1.4. Lung Cancer
      • 14.4.1.5. Melanoma
      • 14.4.1.6. Colorectal Cancer
      • 14.4.1.7. Others
    • 14.4.2. Inflammatory Disorders
    • 14.4.3. Others
  • 14.5. Market Value Forecast By End-user, 2020-2034
    • 14.5.1. Hospital Pharmacies
    • 14.5.2. Independent Pharmacies
    • 14.5.3. Online Pharmacies
  • 14.6. Market Value Forecast By Country/Sub-region, 2020-2034
    • 14.6.1. Brazil
    • 14.6.2. Mexico
    • 14.6.3. Rest of Latin America
  • 14.7. Market Attractiveness Analysis
    • 14.7.1. By Type
    • 14.7.2. By Route of Administration
    • 14.7.3. By Application
    • 14.7.4. By End-user
    • 14.7.5. By Country/Sub-region

15. Middle East & Africa Kinase Inhibitors Market Analysis and Forecast

  • 15.1. Introduction
    • 15.1.1. Key Findings
  • 15.2. Market Value Forecast By Type, 2020-2034
    • 15.2.1. Non-receptor Tyrosine Kinase Inhibitors
      • 15.2.1.1. Bruton's Tyrosine Kinase (BTK) Inhibitors
      • 15.2.1.2. BCR-ABL
      • 15.2.1.3. Janus Kinase (JAK) Inhibitor
      • 15.2.1.4. Mesenchymal Epithelial Transition Growth Factor (c-MET)
      • 15.2.1.5. Spleen Tyrosine Kinase (SYK) Inhibitors
      • 15.2.1.6. Others
    • 15.2.2. Receptor Tyrosine Kinase Inhibitors
      • 15.2.2.1. VEGFR
      • 15.2.2.2. PDGFR
      • 15.2.2.3. EGFR
      • 15.2.2.4. ALK
      • 15.2.2.5. Others
    • 15.2.3. Multikinase Inhibitors
    • 15.2.4. Serine/Threonine Kinase Inhibitors
    • 15.2.5. Protein Kinase C Inhibitors
    • 15.2.6. RHO Kinase Inhibitors
    • 15.2.7. Others
  • 15.3. Market Value Forecast By Route of Administration, 2020-2034
    • 15.3.1. Oral
    • 15.3.2. Parenteral & Others
  • 15.4. Market Value Forecast By Application, 2020-2034
    • 15.4.1. Oncology
      • 15.4.1.1. Breast Cancer
      • 15.4.1.2. Leukemia
      • 15.4.1.3. Renal Cancers
      • 15.4.1.4. Lung Cancer
      • 15.4.1.5. Melanoma
      • 15.4.1.6. Colorectal Cancer
      • 15.4.1.7. Others
    • 15.4.2. Inflammatory Disorders
    • 15.4.3. Others
  • 15.5. Market Value Forecast By End-user, 2020-2034
    • 15.5.1. Hospital Pharmacies
    • 15.5.2. Independent Pharmacies
    • 15.5.3. Online Pharmacies
  • 15.6. Market Value Forecast By Country/Sub-region, 2020-2034
    • 15.6.1. GCC Countries
    • 15.6.2. South Africa
    • 15.6.3. Rest of Middle East & Africa
  • 15.7. Market Attractiveness Analysis
    • 15.7.1. By Type
    • 15.7.2. By Route of Administration
    • 15.7.3. By Application
    • 15.7.4. By End-user
    • 15.7.5. By Country/Sub-region

16. Competition Landscape

  • 16.1. Market Player - Competition Matrix (By Tier and Size of companies)
  • 16.2. Market Share Analysis By Company (2023)
  • 16.3. Company Profiles
    • 16.3.1. Boehringer Ingelheim International GmbH
      • 16.3.1.1. Company Overview
      • 16.3.1.2. Financial Overview
      • 16.3.1.3. Product Portfolio
      • 16.3.1.4. Business Strategies
      • 16.3.1.5. Recent Developments
    • 16.3.2. Novartis AG
      • 16.3.2.1. Company Overview
      • 16.3.2.2. Financial Overview
      • 16.3.2.3. Product Portfolio
      • 16.3.2.4. Business Strategies
      • 16.3.2.5. Recent Developments
    • 16.3.3. AstraZeneca plc
      • 16.3.3.1. Company Overview
      • 16.3.3.2. Financial Overview
      • 16.3.3.3. Product Portfolio
      • 16.3.3.4. Business Strategies
      • 16.3.3.5. Recent Developments
    • 16.3.4. Pfizer, Inc.
      • 16.3.4.1. Company Overview
      • 16.3.4.2. Financial Overview
      • 16.3.4.3. Product Portfolio
      • 16.3.4.4. Business Strategies
      • 16.3.4.5. Recent Developments
    • 16.3.5. F. Hoffmann-La Roche Ltd
      • 16.3.5.1. Company Overview
      • 16.3.5.2. Financial Overview
      • 16.3.5.3. Product Portfolio
      • 16.3.5.4. Business Strategies
      • 16.3.5.5. Recent Developments
    • 16.3.6. Bristol-Myers Squibb Company
      • 16.3.6.1. Company Overview
      • 16.3.6.2. Financial Overview
      • 16.3.6.3. Product Portfolio
      • 16.3.6.4. Business Strategies
      • 16.3.6.5. Recent Developments
    • 16.3.7. Bayer AG
      • 16.3.7.1. Company Overview
      • 16.3.7.2. Financial Overview
      • 16.3.7.3. Product Portfolio
      • 16.3.7.4. Business Strategies
      • 16.3.7.5. Recent Developments
    • 16.3.8. Johnson & Johnson Service, Inc.
      • 16.3.8.1. Company Overview
      • 16.3.8.2. Financial Overview
      • 16.3.8.3. Product Portfolio
      • 16.3.8.4. Business Strategies
      • 16.3.8.5. Recent Developments
    • 16.3.9. Merck & Co., Inc.
      • 16.3.9.1. Company Overview
      • 16.3.9.2. Financial Overview
      • 16.3.9.3. Product Portfolio
      • 16.3.9.4. Business Strategies
      • 16.3.9.5. Recent Developments
    • 16.3.10. Takeda Pharmaceuticals
      • 16.3.10.1. Company Overview
      • 16.3.10.2. Financial Overview
      • 16.3.10.3. Product Portfolio
      • 16.3.10.4. Business Strategies
      • 16.3.10.5. Recent Developments
    • 16.3.11. Eisai Co., Ltd.
      • 16.3.11.1. Company Overview
      • 16.3.11.2. Financial Overview
      • 16.3.11.3. Product Portfolio
      • 16.3.11.4. Business Strategies
      • 16.3.11.5. Recent Developments
    • 16.3.12. GSK Plc.
      • 16.3.12.1. Company Overview
      • 16.3.12.2. Financial Overview
      • 16.3.12.3. Product Portfolio
      • 16.3.12.4. Business Strategies
      • 16.3.12.5. Recent Developments
    • 16.3.13. Eli Lilly
      • 16.3.13.1. Company Overview
      • 16.3.13.2. Financial Overview
      • 16.3.13.3. Product Portfolio
      • 16.3.13.4. Business Strategies
      • 16.3.13.5. Recent Developments
    • 16.3.14. Alcon
      • 16.3.14.1. Company Overview
      • 16.3.14.2. Financial Overview
      • 16.3.14.3. Product Portfolio
      • 16.3.14.4. Business Strategies
      • 16.3.14.5. Recent Developments